Association of dose escalation of octreotide long‐acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors
Open Access
- 26 February 2015
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 4 (6) , 864-870
Abstract
Patients with nonresectable metastatic neuroendocrine tumors (NETs) experience symptoms of hormone hypersecretion including diarrhea, flushing, and bronchoconstriction, which can interfere with quality of life [Anthony and Vinik (2011) Pancreas, 40:987]. Treatment with a long‐acting release formulation of octreotide, a somatostatin analog, can help to alleviate these symptoms. Although high doses of octreotide are often required for adequate symptom control, the relationship between octreotide dose escalation and symptom control in the NET context is not well quantified in the literature. A retrospective chart review was conducted of nonresectable metastatic NET patients who received a dose greater than 30 mg intramuscular octreotide long‐acting formulation (O‐LAR) at any time between January 2005 and December 2011 at the British Columbia Cancer Agency (BCCA). The association between dose escalation of O‐LAR, chromogranin A (CGA), 24‐h urine 5‐hydoxyindoacetate (5‐HIAA), symptom control, and radiological progression was explored. Dose escalation of O‐LAR was associated with improved symptom control in NET patients who were refractory to the standard dose levels. Reduction of serum CGA & 5‐HIAA levels by at least 10% was observed in 31% and 23% respectively. Retrospective review of imaging did not document any reductions in tumor volume. Higher doses of O‐LAR are associated with improved symptom control in NET patients. The variability in tumor marker levels in response to O‐LAR dose escalation may indicate that tumor marker levels may not be an accurate assessment of therapeutic efficacy.Keywords
This publication has 30 references indexed in Scilit:
- Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor DiseaseAnnals of Surgical Oncology, 2010
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical MarkersNeuroendocrinology, 2009
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- Treatment of Neuroendocrine GEP Tumours with Somatostatin AnaloguesDigestion, 2000
- Induction of Apoptosis in Neuroendocrine Tumors of the Digestive System During Treatment with Somatostatin AnalogsActa Oncologica, 1997
- Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients.Gut, 1996
- Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.Gut, 1996
- Somatostatin Analogue Phase I Trials in Neuroendocrine NeoplasmsActa Oncologica, 1993
- Treatment of the Malignant Carcinoid SyndromeNew England Journal of Medicine, 1986